This is exemplified by the recent discovery and use of the BCL-2-specific inhibitor ABT-199 (Venetoclax).13 Venetoclax has proven successful in multiple clinical trials and is a promising new treatment for CLL, certain non-Hodgkin lymphomas and other malignancies.14, 28 Its predecessor, Navitoclax/ABT-263 (the orally bioavailable form of ABT-737), targets not only BCL-2, but also BCL-XL and BCL-W. This evidence concerns the gene BCL2L1 and B-cell chronic lymphocytic leukemia.